Last reviewed · How we verify
Community-acquired bacterial pneumonia — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ceftaroline Fosamil | CEFTAROLINE | Abbvie | 2012-01-01 | |||
| Various | various | Pfizer | Antibiotic | Not specified |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Abbvie · 1 drug in Community-acquired bacterial pneumonia
- Pfizer · 1 drug in Community-acquired bacterial pneumonia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Community-acquired bacterial pneumonia:
- Community-acquired bacterial pneumonia treatment updates — RSS
- Community-acquired bacterial pneumonia treatment updates — Atom
- Community-acquired bacterial pneumonia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Community-acquired bacterial pneumonia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/community-acquired-bacterial-pneumonia. Accessed 2026-06-11.
Related
- Community-acquired bacterial pneumonia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing